Legal & General Group Plc cut its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 17.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 949,786 shares of the insurance provider's stock after selling 197,397 shares during the quarter. Legal & General Group Plc owned approximately 0.79% of Humana worth $240,970,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HUM. Pinnacle Wealth Management Advisory Group LLC lifted its stake in shares of Humana by 3.6% during the 4th quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider's stock valued at $272,000 after buying an additional 37 shares in the last quarter. Atlas Brown Inc. lifted its position in shares of Humana by 0.6% during the fourth quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider's stock worth $1,611,000 after acquiring an additional 38 shares in the last quarter. Mather Group LLC. boosted its holdings in shares of Humana by 21.0% in the fourth quarter. Mather Group LLC. now owns 236 shares of the insurance provider's stock worth $60,000 after acquiring an additional 41 shares during the period. Capital Advisors Ltd. LLC grew its position in shares of Humana by 26.1% in the fourth quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider's stock valued at $53,000 after purchasing an additional 43 shares in the last quarter. Finally, Retirement Planning Co of New England Inc. raised its stake in shares of Humana by 4.7% during the 4th quarter. Retirement Planning Co of New England Inc. now owns 966 shares of the insurance provider's stock valued at $245,000 after purchasing an additional 43 shares during the period. Institutional investors own 92.38% of the company's stock.
Humana Price Performance
NYSE HUM traded down $8.88 on Monday, reaching $286.16. 415,895 shares of the company's stock traded hands, compared to its average volume of 1,747,085. The stock has a market cap of $34.54 billion, a PE ratio of 28.76, a P/E/G ratio of 2.05 and a beta of 0.62. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The stock has a 50-day simple moving average of $265.55 and a 200 day simple moving average of $270.35.
Humana (NYSE:HUM - Get Free Report) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, research analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.
Humana Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.24%. The ex-dividend date is Friday, March 28th. Humana's dividend payout ratio is presently 35.58%.
Analyst Ratings Changes
HUM has been the subject of several analyst reports. Mizuho raised their target price on Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 9th. Piper Sandler raised their price objective on shares of Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a research report on Wednesday, January 15th. Truist Financial upped their target price on shares of Humana from $290.00 to $325.00 and gave the stock a "hold" rating in a report on Friday. Cantor Fitzgerald reissued a "neutral" rating and issued a $290.00 price target on shares of Humana in a report on Wednesday, February 12th. Finally, Barclays boosted their price target on shares of Humana from $270.00 to $322.00 and gave the company an "equal weight" rating in a research report on Friday. Seventeen equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Humana has an average rating of "Hold" and an average target price of $288.60.
Get Our Latest Report on Humana
About Humana
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
